Author: Cardiff Oncology, Inc.

Posted Date:

June 2, 2026

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

Cardiff Oncology, Inc.

June 2, 2026
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

Cardiff Oncology, Inc.

June 1, 2026
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

Cardiff Oncology, Inc.

May 21, 2026
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

Cardiff Oncology, Inc.

May 14, 2026
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cardiff Oncology, Inc.

April 28, 2026
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity

Cardiff Oncology, Inc.

April 27, 2026
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

Cardiff Oncology, Inc.

April 23, 2026
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Cardiff Oncology, Inc.

April 17, 2026
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

Cardiff Oncology, Inc.

March 20, 2026
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

Cardiff Oncology, Inc.

March 19, 2026